Boston Scientific SYNERGY™ Bioabsorbable Polymer Stent Meets Key Performance Endpoints

Boston Scientific reports that its SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System met its primary endpoint in the first successful U.S. pivotal trial of a bioabsorbable polymer stent.

Vagus Nerve Stimulation Study Misses Primary Efficacy Endpoint, But QOL Improved

It’s good news/bad news for Boston Scientific’s Vagus Nerve Stimulation plans as a heart failure therapy. While efficacy endpoints suggested no outcome improvement, patients in the treatment group of the sham controlled study reported quality of life improvement.